These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

272 related items for PubMed ID: 8325938

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Dose-response study and long term effect of the somatostatin analog octreotide in patients with therapy-resistant acromegaly.
    Quabbe HJ, Plöckinger U.
    J Clin Endocrinol Metab; 1989 May; 68(5):873-81. PubMed ID: 2565912
    [Abstract] [Full Text] [Related]

  • 3. Effective clinical response to long term octreotide treatment, with reduced serum concentrations of growth hormone, insulin-like growth factor-I, and the amino-terminal propeptide of type III procollagen in acromegaly.
    Salmela PI, Juustila H, Pyhtinen J, Jokinen K, Alavaikko M, Ruokonen A.
    J Clin Endocrinol Metab; 1990 Apr; 70(4):1193-201. PubMed ID: 2180976
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Results of the International Multicenter Acromegaly Study Group.
    Vance ML, Harris AG.
    Arch Intern Med; 1991 Aug; 151(8):1573-8. PubMed ID: 1872661
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Time course of GH and IGF-1 levels following withdrawal of long-acting octreotide in acromegaly.
    Lorcy Y, Dejager S, Chanson P, French Octreotide LAR Group.
    Pituitary; 2000 Nov; 3(3):193-7. PubMed ID: 11383486
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Sandostatin LAR in acromegalic patients: a dose-range study.
    Fløgstad AK, Halse J, Haldorsen T, Lancranjan I, Marbach P, Bruns C, Jervell J.
    J Clin Endocrinol Metab; 1995 Dec; 80(12):3601-7. PubMed ID: 8530606
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Comparison of monthly intramuscular injections of Sandostatin LAR with multiple subcutaneous injections of octreotide in the treatment of acromegaly; effects on growth hormone and other markers of growth hormone secretion.
    Hunter SJ, Shaw JA, Lee KO, Wood PJ, Atkinson AB, Bevan JS.
    Clin Endocrinol (Oxf); 1999 Feb; 50(2):245-51. PubMed ID: 10396369
    [Abstract] [Full Text] [Related]

  • 13. Octreotide stimulates insulin-like growth factor binding protein-1 (IGFBP-1) levels in acromegaly.
    Ezzat S, Ren SG, Braunstein GD, Melmed S.
    J Clin Endocrinol Metab; 1991 Aug; 73(2):441-3. PubMed ID: 1713220
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Glycemic profile in patients with acromegaly treated with somatostatin analogue.
    Valea A, Carsote M, Ghervan C, Georgescu C.
    J Med Life; 2015 Aug; 8 Spec Issue(Spec Issue):82-6. PubMed ID: 26361517
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Effects of long-acting release octreotide on glucose homeostasis in acromegaly patients after trans-sphenoidal surgery.
    Chen HS, Wu TE, Jap TS, Hsiao LC, Lin HD, Lee SH, Lin SH.
    Horm Metab Res; 2011 Jun; 43(6):433-9. PubMed ID: 21538290
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Administration of high-dose octreotide (Sandostatin) by continuous subcutaneous infusion for the treatment of acromegaly.
    White MC, James RA, Chatterjee S, Mother M, Hall K, Dunne MJ, Baister ER, Kendall-Taylor P.
    Horm Res; 1990 Jun; 33 Suppl 1():13-8; discussion 18-9. PubMed ID: 1972690
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.